HCA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
HCA Healthcare Inc is a good buy for a beginner investor with a long-term investment horizon and $50,000-$100,000 available for investment. The company's strong financial performance, positive analyst sentiment, and encouraging Medicaid program approval outweigh the short-term technical weakness and insider selling. The investor's impatience aligns with the stock's potential for long-term growth.
The stock is currently oversold with an RSI of 10.333, indicating a potential rebound. However, the MACD histogram is negative (-6.479) and contracting, suggesting bearish momentum. The price is near the S1 support level of 480.194, which could act as a strong support zone.
Medicaid SDP program approval in Georgia, expected to boost EBITDA by $83M.
Strong financial performance in Q4 2025, with revenue up 6.72% YoY and EPS up 44.58%.
Positive analyst sentiment with multiple price target increases, including UBS's $635 and TD Cowen's $561 targets.
AI-driven efficiency gains and strong fundamentals cited by analysts.
Insider selling has increased by 1487.91% over the last month, which could indicate caution among insiders.
Short-term technical indicators show bearish momentum.
The broader market (S&P
is down 1.79%, reflecting overall market weakness.
In Q4 2025, HCA Healthcare reported strong financials: Revenue increased to $19.51B (up 6.72% YoY), Net Income rose to $1.878B (up 30.60% YoY), EPS increased to $8.14 (up 44.58% YoY), and Gross Margin improved slightly to 80.07%. These results highlight robust growth and operational efficiency.
Analysts are overwhelmingly positive on HCA, with multiple firms raising price targets recently. RBC Capital highlighted the Medicaid SDP program's impact, while UBS and Mizuho emphasized AI-driven efficiency gains and strong margins. Price targets range from $481 to $635, with most analysts maintaining Buy or Outperform ratings.
